SITC Webinar on Bispecifics and T cell Engagers

Program Overview

Program Summary

The Society for Immunotherapy of Cancer (SITC) will host the webinar, “Bispecifics and T cell Engagers: Practical Strategies for Recognizing and Managing Toxicities,” on Dec. 17, 2025. The virtual program is a free, public event that features invited speakers, audience response systems, and an interactive question and answer period. The multi-stakeholder virtual event will feature expert faculty presenters at the forefront of clinical applications of bispecifics and T cell engagers for hematologic malignancies, solid tumors and toxicity management. The webinar will highlight clinical insights in identifying immune-related adverse events (irAEs) associated with bispecifics and T cell engagers, primarily cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and infection risks, and best practices in irAE management. Topics to be addressed include irAEs associated with bispecifics and T cell engagers and multidisciplinary, collaborative approaches to prevent, recognize, and treat irAEs and improve patient outcomes.

Program Faculty

Program Agenda

Problem Statement

Bispecifics and T cell engagers have revolutionized the treatment of hematologic malignancies, including acute lymphoblastic leukemia, certain lymphomas, and multiple myeloma. Recent approvals of T cell engagers for the treatment of uveal melanoma and small cell lung cancer and ongoing clinical studies of bispecifics and T cell engagers for other indications and diseases indicate that the use of these agents will continue to increase. Despite the high demand and transformative potential of bispecifics and T cell engagers, their safety profiles in real-world clinical settings have not been well-established, and many healthcare professionals need guidance on preventing, identifying, and managing toxicities in order to increase patient access to these modalities and improve patient outcomes.

The SITC webinar, “Bispecifics and T cell Engagers: Practical Strategies for Recognizing and Managing Toxicities,” will provide an up-to-date overview of toxicities and immune-related adverse events from bispecifics and T cell engagers used to treat hematologic malignancies and solid tumors. The program will also address best practices for preventing, recognizing, grading, and treating these events, with a focus on cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infection risk. Didactic presentations, audience response questions, and a dedicated Q&A period will identify clinical strategies, challenges, and opportunities in the field, educating all attendees about the identification and management of toxicities from bispecifics and T cell engagers, ultimately maximizing the benefits of these treatments and maintaining patients’ quality of life.  

Program Goals & Objectives

The primary objective of the SITC webinar, “Bispecifics and T cell Engagers: Practical Strategies for Recognizing and Managing Toxicities,” is to advance the clinical knowledge surrounding toxicities and immune-related adverse events associated with bispecifics and T cell engagers, with a focus on cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infection risk. Secondary goals include discussing best practices for preventing, identifying, grading, and managing the adverse events associated with these modalities, and emphasizing the importance of collaboration within the healthcare team so that toxicities are recognized quickly and managed effectively.

Address the following questions with expert insights:

Target Audience

The 2025 SITC webinar, “Bispecifics and T cell Engagers: Practical Strategies for Recognizing and Managing Toxicities,” aims to reach practicing hematologists, clinical oncologists, emergency physicians, advanced practitioners, nurses, pharmacists, and other allied health professionals who wish to learn up-to-date clinical data for irAEs associated with bispecifics and T cell engagers, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.